Finance

Lists
4547:TYO
Kissei Pharmaceutical Co Ltd
၃,၇၁၀.၀၀ JP¥
+၀.၄၁%
(+၁၅.၀၀) 1D
အောက် ၉, GMT+၉ ၁၅:၃၀:၀၀  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4547...
Open
၃,၇၂၅ JP¥
High
၃,၇၄၅ JP¥
Low
၃,၇၀၅ JP¥
Mkt. cap
ဋေ ၁.၇၃ သ
Avg. vol.
၆.၉၃ သောင်း
Volume
၈.၆၉ သောင်း
Dividend
၃.၂၃%
Quarterly dividend
၃၀ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၁၁.၀၀
52-wk high
၅,၀၄၀ JP¥
52-wk low
၃,၅၀၀ JP¥
EPS
၃၃၇ JP¥
Shares outstanding
၄.၆၇ ကုဋေ
No. of employees
၂ ထောင်
Open
၃,၇၂၅ JP¥
High
၃,၇၄၅ JP¥
Low
၃,၇၀၅ JP¥
Mkt. cap
ဋေ ၁.၇၃ သ
Avg. vol.
၆.၉၃ သောင်း
Volume
၈.၆၉ သောင်း
Dividend
၃.၂၃%
Quarterly dividend
၃၀ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၁၁.၀၀
52-wk high
၅,၀၄၀ JP¥
52-wk low
၃,၅၀၀ JP¥
EPS
၃၃၇ JP¥
Shares outstanding
၄.၆၇ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၅၅ မိနစ်
SolarEdge Technologies (SEDG) Appoints Gokul Krishnan To Lead North America Growth
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၄၃ မိနစ်
GLOBALFOUNDRIES (GFS) Unveils FDX Fusion As Dresden And AI Packaging Plans Advance
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၅၅ မိနစ်
Lineage (LINE) Following Its BSF Extension And The Undervalued Narrative
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees၁.၇၉ ထောင်
Founded၁၉၄၆ ဩ ၉
HeadquartersMatsumoto, Nagano, ဂျပန်
Sector-
Last report
၂၀၂၆ ဇူ ၃၁
Fiscal period
Q1 2027
- / -
Revenue / Est. (JPY)
ဋေ ၂.၃၄ ထ / ဋေ ၂.၂၄ ထ
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၂.၃၆ ထ
ဋေ ၂.၆၈ ထ
ဋေ ၂.၄၈ ထ
ဋေ ၂.၃၄ ထ
Cost of goods sold
ဋေ ၁.၂၀ ထ
ဋေ ၁.၄၅ ထ
ဋေ ၁.၃၉ ထ
ဋေ ၁.၂၀ ထ
Cost of revenue
ဋေ ၁.၂၀ ထ
ဋေ ၁.၄၅ ထ
ဋေ ၁.၃၉ ထ
ဋေ ၁.၂၀ ထ
Research and development expenses
-
-
ဋေ ၂.၂၅ ထ
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
ဋေ ၂.၀၆ ထ
၉၁၄.၉၀ ဋေ
-ဋေ ၁.၅၄ ထ
ဋေ ၁.၀၃ ထ
Operating expense
ဋေ ၂.၀၆ ထ
၉၁၄.၉၀ ဋေ
ဋေ ၁.၀၁ ထ
ဋေ ၁.၀၃ ထ
Total operating expenses
ဋေ ၃.၂၆ ထ
ဋေ ၂.၃၆ ထ
ဋေ ၂.၄၀ ထ
ဋေ ၂.၂၃ ထ
Operating income
-၈၉၄.၆၀ ဋေ
၃၁၅.၅၀ ဋေ
၇၅.၆၀ ကုဋေ
၁၀၉.၆၀ ဋေ
Other non operating income
၁.၀၀ သန်း
၁.၀၀ ကုဋေ
-၁.၀၀ ကုဋေ
၁.၀၀ ကုဋေ
EBT including unusual items
၃၆၆.၂၀ ဋေ
၄၁၉.၆၀ ဋေ
၃၂၈.၄၀ ဋေ
၆၂၉.၂၀ ဋေ
EBT excluding unusual items
-၈၈၂.၂၀ ဋေ
၃၅၁.၇၀ ဋေ
၉၄.၈၀ ကုဋေ
၁၈၁.၆၀ ဋေ
Income tax expense
၃၀.၅၀ ကုဋေ
၉၁.၅၀ ကုဋေ
၄၈.၂၀ ကုဋေ
၁၅၃.၀၀ ဋေ
Effective tax rate
၈.၃၃%
၂၁.၈၁%
၁၄.၆၈%
၂၄.၃၂%
Other operating expenses
-
-
၁၂.၉၀ ကုဋေ
-
Net income
၃၂၆.၅၀ ဋေ
၃၂၃.၀၀ ဋေ
၂၇၆.၅၀ ဋေ
၄၇၂.၃၀ ဋေ
Net profit margin
၁၃.၈၁%
၁၂.၀၅%
၁၁.၁၆%
၂၀.၁၉%
Earnings per share
-
-
-
-
Interest and investment income
၂၁.၂၀ ကုဋေ
၆၁.၄၀ ကုဋေ
၂၂.၄၀ ကုဋေ
၇၂.၉၀ ကုဋေ
Interest expense
-၇.၀၀ သန်း
-၇.၀၀ သန်း
-၈.၀၀ သန်း
-၈.၀၀ သန်း
Net interest expenses
၂၀.၅၀ ကုဋေ
၆၀.၇၀ ကုဋေ
၂၁.၆၀ ကုဋေ
၇၂.၁၀ ကုဋေ
Depreciation and amortization charges
-
-
၂၈၃.၁၀ ဋေ
-
EBITDA
-၇၈၁.၉၀ ဋေ
၄၃၀.၈၈ ဋေ
၁၉၁.၇၀ ဋေ
၂၂၅.၇၀ ဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ